Abiomed Inc.

ABMD

$352.18

+28.3% (1 year change)

Market Cap

$15.9 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$242.73 - $387.40

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

102.77x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $15.9 Billion
Enterprise Value $15.3 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return +28.3%
52-Week High $387.40
52-Week Low $242.73
Beta 0.86
Outstanding Shares 45.4 Million
Avg 30 Day Volume 176 Thousand

Valuation

P/E Ratio 102.77
PEG -64.44
Earnings per Share $3.39
Price to Sales Ratio 17.61
Price to Book Ratio 12.58
Revenue to Enterprise Value 16.41
EBIT to Enterprise Value 58.64
Total Debt to Enterprise Value 0.0
Debt to Equity 0.0

Profitability

Revenue $935 Million
Gross Profit $764 Million
EBIT $262 Million
Net Income $154 Million
Profit Margin 16.51%
Quarterly Earnings Growth (YoY) -159.5%
Return on Equity 11.81%
Return on Assets 10.59%
Return on Invested Capital 19.45%

Insider trades

No purchases

7,701 shares sold (3 transactions)

No purchases

8,900 shares sold (4 transactions)

No purchases

23,487 shares sold (5 transactions)

No purchases

No sells

Q1 2021 Q2 2021 Q3 2021 Q4 2021

About Abiomed Inc.

CEO: Michael Minogue

Employees: 1,371

Industry: Surgical and Medical Instrument Manufacturing

Abiomed is a publicly-traded medical devices company that develops and manufactures the circulatory support device Impella, the world’s smallest heart pump. The company is headquartered in Danvers, Massachusetts and has three additional offices, two in Germany in the cities of Berlin and Aachen, and another in Tokyo, Japan. Michael R. Minogue is Chairman, CEO & President of the company, with Dr. Thorsten Siess as Chief Technology Officer, Dr. Chuck Simonton as Chief Medical Officer and Dr. David M. Weber as Chief Operating Officer. According to Bloomberg, the company "engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients". As of 2019, the company had secured five FDA approvals and 715 patents with 622 pending. For fiscal year 2019, Abiomed reported $769.4 million in revenue and reported diluted earnings per share was $5.61 for the year. Abiomed was founded in Danvers, Massachusetts by David M. Lederman in 1981 as Applied Biomedical Corporation. That year, the company commenced the development of an artificial heart. Funded by federal research grants, Lederman partnered with The Texas Heart Institute to develop the AbioCor, a grapefruit-sized electromagnetic device with an internal battery that completely replaces the heart without wires or tubes passing through the skin. In July 2001, AbioCor became the first artificial heart successfully implanted in a patient, where it pumped more than 20 million times. Fourteen of the AbioCor devices were implanted, during clinical trials from 2001 to 2004, with the longest-living recipient surviving 512 days. The AbioCor won FDA approval in 2006 for patients who are near death and do not qualify for a heart transplant.

Similar stocks

Teleflex Incorporated
Boston Scientific Corp.
Stereotaxis Inc
Atricure Inc

News

Zacks Investment Research Downgrades Abiomed (NASDAQ:ABMD) to Sell

Zacks Investment Research Downgrades Abiomed (NASDAQ:ABMD) to Sell

Zacks Investment Research downgraded shares of Abiomed (NASDAQ:ABMD) from a hold rating to a sell rating in a report published on Tuesday morning, Zacks.com reports. Zacks Investment Research curre...

 Dakota Financial News Dakota Financial News, 3 days ago
Abiomed (ABMD) Stock Jumps 5.9%: Will It Continue to Soar?

Abiomed (ABMD) Stock Jumps 5.9%: Will It Continue to Soar?

Abiomed (ABMD) shares rallied 5.9% in the last trading session to close at $332.47. This move can be attributable to notable volume with a higher number of shares being traded than in a typical ses...

iShook Finance iShook Finance, 19 days ago
Cardiac Assist Devices Market 2021 Global Analysis by Key Players  Terumo Corporation, BERLIN HEART GmbH, MAQUET GmbH, Teleflex Incorporated, ABIOMED Inc, Abbott Laboratories, Medtronic PLC, CARMAT SA

Cardiac Assist Devices Market 2021 Global Analysis by Key Players Terumo Corporation, BERLIN HEART GmbH, MAQUET GmbH, Teleflex Incorporated, ABIOMED Inc, Abbott Laboratories, Medtronic PLC, CARMAT SA

Cardiac Assist Devices or CADs are the heart pumping devices that work along-side heart and are used to stabilize the pumping ability and proper maintenance of the blood flow in the body. Increase ...

OpenPR OpenPR, about 1 month ago